Since thrombopoietin receptor agonists (TPO-RAs) eltrombopag and romiplostim were licensed in the United States for treatment of immune thrombocytopenia (ITP) in 2008, their use has progressively increased, and they are currently available in more than 100 countries (1). Here, MPL is linked to autoimmune thrombocytopenic purpura.